|Issues in Immunodiagnostics Symposium
Tumor Markers: From Bench to Bedside
The AACC Clinical and Diagnostic Immunology Division
With funding from an education grant provided by
Siemens Health Care Diagnostics
Originally presented during the AACC Annual Meeting on
July 26, 2008
Presentations and CE Credit
The presentations in this webcast were originally made on July 26, 2008, in Washington, DC, prior to the AACC Annual Meeting. The contents include three 30-minute presentations. The CDI Division is making this webcast and CE credit available free as a division membership service.
The American Association for Clinical Chemistry designates this program for a maximum of 2.0 ACCENT© credit hours toward the AACC Clinical Chemist’s Recognition Award. AACC is an approved provider of continuing education for clinical laboratory scientists in the states of California, Florida, Louisiana, Montana, Nevada, North Dakota, Rhode Island, and West Virginia.
AACC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education activities for physicians. AACC designates this educational activity for up to 2 hours of Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spends in the educational activity.
To obtain continuing education credit, view the three online presentations, then follow directions under CE Credit.
The deadline for obtaining credit for this activity is July 1, 2009.
Target Audience and Speaker Disclosures
All presentations are copyright© AACC
The presentations are best viewed with these system requirements
Computer: 500MHz with 128MB RAM
Operating Systems: Windows 98, ME, 2000, XP, Vista or MAC OSX
Players & Plugins: Adobe Flash Player 8 or higher
Browsers: View Adobe's web browser requirements
Audio: Functioning sound card with attached speakers installed
Target audience: Clinical chemists, clinical pathologists, clinicians, clinical laboratory scientists/medical technologists.
Content level: Intermediate.
Release date: September 15, 2008.
The following speakers have disclosed financial relationships with the companies noted: Dr. Liu disclosed that he has Board/Committee membership with Inanovate, Inc; however, he does not mention/discuss any of the products/services of this company in his presentation.
The other authors have disclosed that they have no financial interests in a company as defined in the AACC Policy on Conflict of Interest.
Learning Objectives by Presentation
After Dr. Liu’s presentation, the learner should be able to:
- Describe the current status and need for tumor biomarkers in the context of prostate cancer
- Provide examples of protein microarrays and their use in biomarker discoveries
- Discuss the downstream applications of protein microarrays as they relate to the development of a highly personalized approach to medicine
After Dr. Beveridge’s presentation, the learner should be able to:
- List the major uses for serum-based tumor markers in the diagnosis and monitoring of cancer patients
- Provide examples of tumor markers shown to have particular clinical relevance
- Describe the applications of new techniques to measure tumor markers as they relate to the therapy of hematological malignancies
After Dr. Gutman’s presentation, the learner should be able to:
- Describe the approach taken by the FDA to the approval of new tumor markers
- List new criteria important for the evaluation of clinical efficacy of tumor markers
- Describe how new techniques to measure tumor markers should be incorporated in routine clinical use